Melbourne, Australia; 4 June 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.

More than 45,000 oncology clinicians, researchers, and pharmaceutical company representatives from around the world attended the ASCO Annual Meeting this year. Highly sought-after oral presentation slots are granted to studies that include significant breakthroughs and technologies likely to improve clinical oncology practice and patient outcomes.

The clinical investigators involved in both the DEP® irinotecan and DEP® cabazitaxel studies are excited by the clinical data for these dendrimer-based medicines. They were highly impressed with the selection of both abstracts for oral presentation at the ASCO Meeting, describing this as a significant achievement that recognises the positive clinical study findings for cancer patients.

The DEP® irinotecan ASCO Meeting abstract (#3014) has been published in the Journal of Clinical Oncology (JCO) (Volume 42, Number 16)[1]. Dr Jia (Jenny) Liu, MD PhD FRACP, Medical Oncologist and Principal Investigator of the DEP® irinotecan trial at the Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney, delivered the presentation overnight.

View/download the ASX Announcement: DEP® irinotecan presentation at ASCO 2024 Annual Meeting.

[1] https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3014